Cardiometabolic Effects Explained with GLP-1 Receptor Therapy

Find out about GLP-1 receptor therapy and its significance in improving cardiometabolic health and wellness.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I present a comprehensive, easy-to-follow journey through the modern risk-reduction paradigm for type 2 diabetes that integrates cardiovascular and renal health. We will explore why care has shifted from a glucose-only focus to a broader strategy driven by the FDA’s cardiovascular outcome trial (CVOT) mandate, and how this led to breakthrough findings for SGLT2 inhibitors and GLP-1 receptor agonists. I synthesize landmark trial results, explain the physiology that underpins heart and kidney protection, and show how these medications reduce major adverse cardiovascular events (MACE), heart failure hospitalizations, and kidney disease progression. I also share how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas integrates integrative chiropractic care, functional medicine, rehabilitation, and personal injury services with medical oversight from Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with over 40 years of experience. Through detailed case examples and practical guidance, I explain how we build individualized programs that combine medication strategies with lifestyle, biomechanics, and nervous system regulation to achieve durable, whole-person outcomes.

Our Integrated Care Model: Medical Oversight Meets Chiropractic and Functional Medicine

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, our treatment philosophy is rooted in a multidisciplinary, integrative model that aligns medical direction with chiropractic and functional medicine to address complex metabolic and musculoskeletal needs.

• Medical Director and Collaborative Physician: Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, NPI #1164426749, Texas MD License #J2933, brings over 40 years of frontline internal medicine experience to guide diagnostics, laboratory oversight, prescription management, and risk stratification for conditions such as type 2 diabetes, hypertension, coronary artery disease, heart failure, and chronic kidney disease (CKD).
• Integrative Chiropractic Care and Functional Medicine: As a chiropractor and functional medicine practitioner (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST), I focus on biomechanics, autonomic nervous system regulation, and root-cause lifestyle interventions to improve mobility, reduce inflammation, and enhance metabolic resilience. This includes personalized exercise prescriptions, anti-inflammatory nutrition, and stress modulation strategies to improve insulin sensitivity and cardiometabolic fitness.
• Rehabilitation and Personal Injury Services: Our rehabilitation team supports patients recovering from accidents or managing chronic pain and deconditioning through targeted mobility and strength programs to increase physical activity safely.
• Unified, Risk-Based Treatment Plans: We coordinate pharmacologic therapy (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) under medical oversight, while I develop individualized protocols across nutrition, movement, sleep, and stress. This synergy allows us to optimize cardiac, renal, and metabolic health.

This approach reflects what I have observed and shared through my ongoing clinical work and insights at wellnessdoctorrx.com and my professional updates on LinkedIn, as we blend evidence-based medicine with functional and rehabilitative strategies to help patients achieve durable health improvements.

Why Diabetes Care Changed: From Glucose-Centric to Cardiovascular and Renal Risk Reduction

For decades, diabetes management prioritized lowering blood glucose and A1C. Yet patients with diabetes face markedly elevated risks of atherosclerotic cardiovascular disease (ASCVD)—including heart attack, stroke, and peripheral arterial disease—and disproportionate mortality following myocardial infarction even when glucose is controlled (American Diabetes Association Professional Practice Committee, 2023; 2024).

The shift began in 2008 when the U.S. Food and Drug Administration (FDA) required long-term CVOTs for all new anti-diabetic drugs to rule out excess MACE (cardiovascular death, nonfatal MI, nonfatal stroke). This mandate corrected shortcomings of older trials that were too short or underpowered to detect cardiovascular harms. The unforeseen outcome: several new therapies not only proved cardiovascular safety but demonstrated cardiovascular and renal superiority, prompting sweeping guideline changes (American Diabetes Association Professional Practice Committee, 2023; 2024).

• Key takeaway: Modern management targets comprehensive risk reduction—prioritizing blood pressure control, lipid optimization, weight management, smoking cessation, and activity—while using therapies with proven cardiovascular and renal protection (American Diabetes Association Professional Practice Committee, 2023; 2024).

ADA’s Risk-Reduction Algorithm: When to Prioritize SGLT2 and GLP-1 Agents

The ADA Standards of Care now recommend that for patients with type 2 diabetes and established ASCVD, heart failure, CKD, or high risk for these conditions, treatment should include lifestyle therapy and a GLP-1 receptor agonist or SGLT2 inhibitor with proven benefit (American Diabetes Association Professional Practice Committee, 2023; 2024).

• ASCVD or high-risk profiles: Prefer a GLP-1 receptor agonist (e.g., liraglutide, semaglutide, dulaglutide) for robust MACE reduction; an SGLT2 inhibitor is an excellent alternative or addition (Marso et al., 2016; Marso et al., 2016; Husain et al., 2019; Gerstein et al., 2019).
• Heart failure (HF): Choose an SGLT2 inhibitor first-line due to strong reductions in HF hospitalizations and composite CV outcomes, including for HF with reduced and preserved ejection fraction (McMurray et al., 2019; Anker et al., 2021).
• CKD: Prefer an SGLT2 inhibitor to slow kidney disease progression and reduce renal/CV death; some GLP-1 agents also show nephroprotective signals (The EMPA-KIDNEY Collaborative Group, 2023; Neal et al., 2017; McMurray et al., 2019; Husain et al., 2019).

In practice, many high-risk patients benefit from combination therapy—pairing an SGLT2 inhibitor with a GLP-1 receptor agonist to cover heart, kidney, and weight management simultaneously.

SGLT2 Inhibitors: How They Protect the Heart and Kidneys

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin) emerged as unexpected cardioprotective and nephroprotective agents once CVOTs matured (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019).

• EMPA-REG OUTCOME (empagliflozin): Reduced MACE, cardiovascular death, and all-cause mortality (Zinman et al., 2015).
• CANVAS Program (canagliflozin): Lowered MACE and heart failure hospitalizations (Neal et al., 2017).
• DECLARE-TIMI 58 (dapagliflozin): Strong reduction in HF hospitalizations; neutral on MACE (Wiviott et al., 2019).
• VERTIS-CV (ertugliflozin): Significant reduction in heart failure hospitalizations.

Physiological mechanisms driving these benefits are multifaceted:

• Hemodynamic and natriuretic effects: SGLT2 inhibition induces mild osmotic diuresis and natriuresis, lowering plasma volume and systolic blood pressure (~5 mmHg). This reduces ventricular preload and afterload, easing cardiac stress.
• Renal hemodynamics: By enhancing distal sodium delivery, SGLT2 agents restore tubuloglomerular feedback, lowering intraglomerular pressure. This protects glomeruli against hyperfiltration injury—a key driver of CKD progression.
• Metabolic remodeling: Agents promote mild ketosis, improving myocardial efficiency by providing ketones, an energetically favorable substrate for the heart. They also reduce systemic inflammation, oxidative stress, and fibrosis, frequently improving vascular and myocardial resilience.
• Weight and glycemia: Modest weight loss (about 5–7 pounds) and an average A1C reduction of ~1% further lower cardiometabolic risk.

The field then advanced with dedicated HF and CKD trials, including:

• DAPA-HF (HFrEF): ~26% relative risk reduction in CV death or worsening HF, irrespective of diabetes status (McMurray et al., 2019).
• EMPEROR-Reduced & EMPEROR-Preserved: ~25% and ~21% relative risk reductions in composite HF outcomes, demonstrating efficacy in HFrEF and HFpEF (Anker et al., 2021).
• DAPA-CKD and EMPA-KIDNEY: Robust nephroprotection, including early stopping for overwhelming efficacy (The EMPA-KIDNEY Collaborative Group, 2023; McMurray et al., 2019).

Practical pearls I see in clinic:

• Combination options: Many SGLT2s are available with metformin (often extended-release) to simplify dosing and reduce GI effects.
• Low eGFR use: Cardiorenal benefits persist even as glycemic lowering wanes at low eGFR, allowing organ-protective use in CKD.
• Counseling: Morning dosing to reduce nocturia, vigilant hydration, and genital hygiene to mitigate mycotic infections; consider topical antifungals first if needed.

GLP-1 Receptor Agonists: Incretin Biology and Cardiometabolic Power

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, exenatide) restore the incretin effect, a gut-pancreas signaling pathway that amplifies glucose-dependent insulin secretion after meals. In type 2 diabetes, native incretin hormone responses are blunted.

Core actions:

• Stimulates insulin, inhibits glucagon: GLP-1 agonists boost insulin only when glucose is elevated and suppress glucagon-mediated hepatic glucose output, reducing postprandial hyperglycemia.
• Slows gastric emptying: Extends satiety and reduces intake, central to weight loss; also explains GI side effects (nausea, fullness).
• Central appetite modulation: Activation of hypothalamic GLP-1 receptors enhances satiety and decreases cravings.

Landmark CVOTs and renal findings:

• LEADER (liraglutide): Significant MACE reduction in a population with high baseline CV risk (Marso et al., 2016).
• SUSTAIN-6 (semaglutide injection): Confirmed robust MACE reduction (Marso et al., 2016).
• REWIND (dulaglutide): Demonstrated benefit in many patients with risk factors only, supporting primary prevention (Gerstein et al., 2019).
• PIONEER 6 (oral semaglutide): Showed cardiovascular safety and benefit in the first oral GLP-1 formulation (Husain et al., 2019).
• FLOW (semaglutide, nephropathy): Stopped early for positive renal outcomes, underscoring nephroprotective potential.

Why GLP-1s protect the heart and kidneys:

• Weight loss: reduces blood pressure, improves lipid profiles, and lowers the inflammatory burden.
• Direct vascular and cardiac effects: GLP-1 receptors in myocardium and vasculature may enhance contractility, glucose uptake, and natriuresis, easing cardiac filling pressures.
• Anti-inflammatory and anti-atherogenic effects: Decrease plaque inflammation and may stabilize atherosclerotic lesions.

Side-effect management and safety considerations:

• GI effects: Start at the lowest dose and titrate slowly; encourage hydration, smaller meals, reduced dietary fat, and adequate protein.
• Gallbladder risk: Rapid weight loss and decreased cholecystokinin stimulation can increase gallstone risk—monitor symptoms.
• Pancreatitis: Large contemporary datasets show no significant increased long-term risk; improved metabolic profiles may lower lifetime risk.
• AKI risk with dehydration: Monitor at-risk patients; prioritize hydration and early intervention for GI intolerance.
• Thyroid C-cell warning: Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2.
• Peri-anesthesia considerations: Hold daily formulations on the day of the procedure and weekly formulations 1 week before anesthesia or deep sedation.

Over-Basalization: When Escalating Basal Insulin Isn’t the Answer

In real-world care, I frequently see patients whose basal insulin doses have drifted higher and higher without achieving A1C goals—what we call over-basalization. Pharmacokinetic data show diminishing returns above 0.5 units/kg/day for obese patients with type 2 diabetes. Clinical markers include:

• Basal insulin >0.5 units/kg/day
• Postprandial glucose >180 mg/dL
• A1C above goal with acceptable fasting glucose
• >50 mg/dL bedtime-to-morning drop

In these cases, adding prandial insulin may lower A1C but often causes weight gain and increases the risk of hypoglycemia. A GLP-1 receptor agonist typically provides a better next step—targeting postprandial hyperglycemia via the incretin mechanism, promoting weight loss, lowering CV risk, and avoiding hypoglycemia.

When initiating GLP-1 therapy:

• Start low, go slow: Titrate cautiously over weeks to minimize GI side effects.
• In-office teaching: Demonstrate pen-technique to build patient confidence and adherence.
• Choose standalone agents over fixed ratios when greater incretin dosing flexibility is needed.

Case Integration: Loretta and Tony

Real cases illustrate how we apply the algorithm and integrative care.

• Loretta, 72: Type 2 diabetes (A1C 8.1%), CAD post-stents, eGFR 55 mL/min/1.73m²; on metformin plus sitagliptin.

• Plan: Replace sitagliptin (a DPP-4 inhibitor without CV benefit) with an SGLT2 inhibitor. Prefer a combination pill with extended-release metformin for once-daily simplicity. Focus on hydration and infection prevention, and reinforce lifestyle changes to lower A1C and protect the heart and kidneys. This aligns with ADA risk-based recommendations and nephroprotective evidence (Zinman et al., 2015; Neal et al., 2017; The EMPA-KIDNEY Collaborative Group, 2023; American Diabetes Association Professional Practice Committee, 2023).

• Tony, 62: Type 2 diabetes (A1C 8.2%), proteinuria, obesity (BMI 32.5), on high-dose basal insulin (65 units), metformin, SGLT2 inhibitor, statin, ARB; fasting glucose 110–150 mg/dL with postprandial spikes 160–200 mg/dL.

• Problem: Classic over-basalization with elevated post-meal glucose.
• Plan: Add a GLP-1 receptor agonist—semaglutide, dulaglutide, or liraglutide—before considering prandial insulin. Expect A1C reduction, weight loss, an improved CV risk profile, and a lower risk of hypoglycemia. Use a standalone GLP-1 to titrate to an effective dose. Integrate chiropractic and rehab to reduce pain, improve mobility, and support exercise; implement anti-inflammatory, low-glycemic nutrition and stress modulation to enhance metabolic control (Marso et al., 2016; Marso et al., 2016; Gerstein et al., 2019; Husain et al., 2019).

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

How Integrative Chiropractic Care Fits: Biomechanics, Autonomics, and Metabolic Health

In our clinic, chiropractic care is not an adjunct—it is a core pillar that synergizes with medical therapy:

• Biomechanical optimization: Targeted spinal and extremity adjustments, soft-tissue work, and mobility corrections reduce pain and improve joint mechanics, making it easier and safer to achieve the physical activity necessary for insulin sensitivity, weight control, and cardiovascular conditioning. As patients lose weight (e.g., on GLP-1 therapy), biomechanics change; proactive chiropractic care prevents new strain patterns and supports healthy posture and gait.
• Autonomic nervous system regulation: Adjustments influence sympathetic-parasympathetic balance. Moving from a “fight-or-flight” to a “rest-and-digest” state improves glycemic control, sleep quality, and gastrointestinal motility—particularly valuable when gastric emptying is slowed by GLP-1 therapy.
• Functional medicine and nutrition: We personalize anti-inflammatory and low-glycemic plans emphasizing protein adequacy, fiber diversity, hydration, micronutrient density, and gut health. This approach reduces systemic inflammation, stabilizes postprandial glucose, and supports weight loss while protecting lean mass.
• Rehabilitation and resistance training: To counter lean mass loss during rapid weight reduction, our rehab team prescribes progressive resistance exercise and functional movement patterns that maintain muscle, metabolic rate, and bone density—all crucial for long-term cardiometabolic resilience.

This integrated framework—medical direction by Dr. Cardenas and chiropractic-functional rehabilitation guided by me—ensures our patients receive comprehensive, evidence-based, and personalized care.

Practical Considerations and Patient Education

To help patients succeed, we emphasize:

• Medication timing and hydration: Morning dosing for SGLT2s; sustained hydration to prevent dizziness, hypotension, or AKI risk when GI side effects occur.
• Hygiene and infection prevention: Daily genital hygiene to reduce mycotic infection risk; consider topical antifungals early if symptoms arise.
• Nutrition strategies with GLP-1s: Smaller meals, lower fat intake, adequate protein to minimize nausea and support muscle preservation.
• Perioperative planning: Coordinate with anesthesia for GLP-1 timing holds.
• Monitoring and follow-up: Regular labs for A1C, lipids, kidney function, and urine albumin; blood pressure and weight checks; symptom review for gallbladder or dehydration concerns.

Where the Field Is Going: Beyond Glycemia to Systemic Health

Research continues to expand indications:

• Heart failure and CKD without diabetes: SGLT2s benefit cardiac and renal outcomes even in non-diabetic populations, underscoring hemodynamic, metabolic, and anti-inflammatory mechanisms (McMurray et al., 2019; Anker et al., 2021; The EMPA-KIDNEY Collaborative Group, 2023).
• GLP-1 expansions: Trials investigate benefits in metabolic-associated steatohepatitis (MASH), neuropsychiatric conditions, neurodegenerative diseases, and PCOS, leveraging anti-inflammatory and central appetite pathways with promising early findings (American Diabetes Association Professional Practice Committee, 2024; Husain et al., 2019; Smits & Van Raalte, 2021).

Our team continuously translates these findings into practical care plans, integrating safe medication protocols with lifestyle, biomechanics, and autonomic regulation to achieve sustained outcomes.

Bringing It All Together: A Modern, Holistic Strategy

The modern era in diabetes care embraces a risk-based paradigm. Starting with lifestyle foundations, we apply therapies with proven cardiorenal benefits—SGLT2 inhibitors and GLP-1 receptor agonists—and we integrate chiropractic, functional medicine, and rehabilitation to align metabolic, vascular, renal, and musculoskeletal health.

• For ASCVD/high risk: Use GLP-1s (with or without SGLT2s) to reduce MACE and support weight control.
• For HF: Prioritize SGLT2s to lower HF hospitalizations and improve cardiac outcomes.
• For CKD: Use SGLT2s to slow progression and reduce renal/CV events.
• For over-basalization: Prefer GLP-1s over adding prandial insulin to lower A1C with weight loss and less hypoglycemia.

By uniting medical oversight from Dr. Maria Guadalupe Cardenas, MD, with my integrative chiropractic and functional approach, our practice delivers personalized, evidence-based care that respects the complexity of cardiometabolic disease while empowering patients to achieve lasting health.

References

• American Diabetes Association Professional Practice Committee. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023. Diabetes Care, 46(Suppl 1), S140–S157.
• American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement 1), S158–S178.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., … & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., … & Avezum, A. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130.
• Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., … & Mann, J. F. E. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841–851.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., … & DeMets, D. L. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., … & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657.
• Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563.
• The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127.
• Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., … & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347–357.
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., … & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.

SEO tags: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular disease, chronic kidney disease, heart failure, integrative chiropractic care, functional medicine, risk reduction, ASCVD, DAPA-HF, EMPA-REG OUTCOME, nephroprotection, cardioprotection, diabetes management, evidence-based medicine, El Paso TX, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, over-basalization, semaglutide, dulaglutide, liraglutide, empagliflozin, dapagliflozin, canagliflozin, incretin effect, autonomic nervous system, rehabilitation, personal injury care, Mission Plaza Injury Medical Clinic, wellnessdoctorrx.com, LinkedIn Dr. Alex Jimenez